Citations

Showing 10 of 108162 citations.

TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?
Giannini, Caterina , Giannini, Caterina , Giangaspero, Felice

Mayo Clinic

Neuro-Oncology | February 23, 2021 | Volume: 23 | Issue: 6 | Pages: 865-866

10.1093/neuonc/noab052 | PMID 33660766 Get It

An evolutionary mismatch narrative to improve lifestyle medicine: a patient education hypothesis
Basile, Anthony J. , Renner, Michael, Hidaka, Brandon H. , Sweazea, Karen L. , Hidaka, Brandon

Mayo Clinic

Evolution, Medicine, and Public Health | February 23, 2021 | Volume: 9 | Issue: 1 | Pages: No page available

10.1093/emph/eoab010 | PMID 33747517 Get It

Abstract An evolutionary perspective provides a unifying explanation for the modifiable risk factors and lifestyle-based interventions for the leading causes of morbidity and mortality globally. Non-communicable diseases develop from an evolutionary mismatch between the prior environment and modern patterns of behavior; however, it is unclear whether an evolutionary mismatch narrative could promote positive behavior change in patients. We hypothesize that educating patients about evolutionary mismatch could augment efforts to improve healthful behavior. Specifically, explaining the ‘why’ behind what is being recommended could promote health literacy and adherence. Furthermore, we offer suggestions of how clinicians could educate patients about evolutionary mismatch for key-lifestyle factors, diet and physical activity, as well as several specific modern diseases. We also consider how to sidestep patients’ skepticism of evolutionary theory. Here, we lay the groundwork for research on how educating patients with an evolutionary mismatch narrative could impact health behaviors and improve outcomes.
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer
Merritt, Melissa A. , Strickler, Howard D. , Hutson, Alan D. , Rohan, Thomas E. , Xue, Xiaonan , Brinton, Louise A. , Yu, Kai , Miller, David S. , Ramirez, Nilsa C. , Lankes, Heather A. , Birrer, Michael J. , Huang, Gloria S. , Gunter, Marc J. , Brinton, Louise A , Yu, Herbert , Miller, David S , Huang, Gloria S , Gunter, Marc J , Hutson, Alan D , Einstein, Mark H. , Sherman, Mark E.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 23, 2021 | Volume: 30 | Issue: 4 | Pages: 719-726

10.1158/1055-9965.epi-20-1613 | PMID 33622671 Get It

Abstract Background: The influence of sex hormone and insulin/insulin-like growth factor (IGF) axis signaling on endometrial cancer recurrence is unknown. We evaluated these pathways in a prospective cohort of Gynecologic Oncology Group (GOG)0210 trial endometrial adenocarcinoma patients. Methods: Stage II–IV patients (N = 816) were included in this study. Pretreatment specimens were tested for tumor mRNA and protein expression of IGF1, IGF2, IGF-binding proteins (IGFBP)-1 and -3, insulin (IR) and IGF-I receptors (IGF1R), phosphorylated IR/IGF1R (pIGF1R/pIR), and estrogen (ER) and progesterone receptors (PR) using qPCR and IHC. Serum concentrations of insulin, IGF-I, IGFBP-3, estradiol, estrone, and sex hormone binding globulin were measured. HRs and 95% confidence intervals (CI) for progression-free survival were calculated from Cox models adjusting for age, stage, and grade. Results: Recurrence occurred in 280 (34%) cases during a median of 4.6 years of follow-up. ER positivity (HR, 0.67; 95% CI, 0.47–0.95), IR positivity (HR, 0.53; 95% CI, 0.29–0.98), and circulating IGF-I (highest vs. lowest quartile: HR, 0.66; 95% CI, 0.47–0.92) were inversely associated with recurrence risk. Circulating estradiol (highest vs. lowest tertile: HR, 1.55; 95% CI, 1.02–2.36) and pIGF1R/pIR positivity (HR, 1.40; 95% CI, 1.02–1.92) were associated with increased recurrence risk. Conclusions: Circulating estradiol and tumor tissue phosphorylated (activated) IGR1R/IR were independently associated with higher risk of recurrence in patients with endometrial cancer. Impact: This study may inform future clinical trials of endocrine-targeted adjuvant therapies in patients with endometrial cancer that could include baseline assessment of serum and tissue biomarkers of estradiol and insulin signaling pathways.
Post Dural Puncture Headache Following Intrathecal Drug Delivery System Placement
Neuman, Stephanie

Mayo Clinic

Pain Physician | February 23, 2021 | Volume: 2;16 | Issue: 2;3 | Pages: 101-107

10.36076/ppj.2013/16/101 Get It

Background: Placement of an intrathecal drug delivery system (IDDS) may provide substantial benefit to certain patients. However, placement of these devices is not without complications, and minimal data exist describing the rates of these complications. Specifically, there is a paucity of data describing the incidence of post dural puncture headache (PDPH) following IDDS placement. Objectives: The aim of this study was to identify the incidence and treatment course of PDPH following placement of an IDDS in a retrospective review. Study Design: Retrospective assessment of medical records. Setting: Department of Pain Medicine and Anesthesiology, Mayo Clinic, Rochester, MN. Methods: Following IRB approval, 319 IDDS surgical reports in 285 patients were identified retrospectively over a 20 year study time period. We report demographic information, number of dural punctures, techniques for sealing dural leak, details, and treatment course of PDPH in this population. Results: Symptoms of PDPH were recognized in 73 individual cases (23% of total procedural volume). Younger patient age was the only statistically significant characteristic in predicting development of a PDPH. There were no statistically significant differences found in regards to other risk factors for PDPH development or treatment strategy employed. Seventy-nine percent of PDPH patients were successfully managed with conservative non-interventional therapies (bedrest, IV fluids, analgesics, antiemetics), while 21% required progression to epidural blood or fibrin glue patch procedures for full resolution of symptoms. Limitations: Limitations include the retrospective design of the study as well as the potential for undocumented or improperly documented surgical techniques and/or events. Conclusion: Though the development of PDPH after IDDS implantation was found to be fairly common (23% incidence), the majority of these patients had self-limited symptoms that resolved with conservative medical management. Epidural blood patch or application of epidural fibrin glue was therapeutically successful for the remainder of PDPH patients who were refractory to conservative measures. Key words: Pain, intrathecal drug delivery system, pain pump, morphine, baclofen, postdural puncture headache, spinal headache
Reply to: Implication of hemodynamic ramp tests in patients with left ventricular assist devices
Rosenbaum, Andrew , Ternus, Bradley , Jentzer, Jacob C.

Mayo Clinic

Artificial Organs | February 23, 2021 | Volume: 45 | Issue: 2 | Pages: 188-188

10.1111/aor.13903 | PMID 33620742 Get It

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Nowakowski, Grzegorz S. , Chiappella, Annalisa , Gascoyne, Randy D. , Scott, David W. , Zhang, Qingyuan , Jurczak, Wojciech , Özcan, Muhıt , Hong, Xiaonan, Zhu, Jun , Jin, Jie , Bergua, Juan , Piazza, Francesco , Móciková, Heidi , Molinari, Anna Lia, Yoon, Dok Hyun , Tani, Monica , Kato, Koji , Czuczman, Myron S., Hersey, Sarah, Kilcoyne, Adrian , Russo, Jacqueline, Hudak, Krista, Zhang, Jingshan , Wade, Steve, Vitolo, Umberto , Song, Yuqin , Bergua, Juan Miguel , Piazza, Francesco , Yamamoto, Kazuhito , Witzig, T.E. , Vitolo, Umberto , Scott, David W , Jurczak, Wojciech , Belada, David , Cavallo, Federica , Izutsu, Koji , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2021 | Volume: 39 | Issue: 12 | Pages: 1317-1328

10.1200/jco.20.01366 | PMID 33621109 Get It

PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent lenalidomide to R-CHOP improved outcomes in ABC-type DLBCL. The goal of the global, phase III ROBUST study was to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL. METHODS Histology and cell-of-origin type were prospectively analyzed by central pathology prior to random assignment and study treatment. Patients with ABC-DLBCL received lenalidomide oral 15 mg/d, days 1-14/21 plus standard R-CHOP21 versus placebo/R-CHOP21 for six cycles. The primary end point was progression-free survival (PFS) per independent central radiology review. RESULTS A total of 570 patients with ABC-DLBCL (n = 285 per arm) were stratified by International Prognostic Index score, age, and bulky disease, and randomly assigned to R2-CHOP or placebo/R-CHOP. Baseline demographics were similar between arms. Most patients completed six cycles of treatment: 74% R2-CHOP and 84% placebo/R-CHOP. The most common grade 3/4 adverse events for R2-CHOP versus placebo/R-CHOP were neutropenia (60% v 48%), anemia (22% v 14%), thrombocytopenia (17% v 11%), and leukopenia (14% v 15%). The primary end point of PFS was not met, with a hazard ratio of 0.85 (95% CI, 0.63 to 1.14) and P = .29; median PFS has not been reached for either arm. PFS trends favoring R2-CHOP over placebo/R-CHOP were seen in patients with higher-risk disease. CONCLUSION ROBUST is the first DLBCL phase III study to integrate biomarker-driven identification of eligible ABC patients. Although the ROBUST trial did not meet the primary end point of PFS in all patients, the safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
Lung mass density prediction using machine learning based on ultrasound surface wave elastography and pulmonary function testing
Bartholmai, Brian J. , Kalra, Sanjay , Osborn, Thomas G. , Zhou, Boran , Osborn, Thomas, Bartholmai, Brian J , Zhang, Xiaoming

Mayo Clinic

The Journal of the Acoustical Society of America | February 23, 2021 | Volume: 149 | Issue: 2 | Pages: 1318-1323

10.1121/10.0003575 | PMID 33639787 Get It

Objective: The objective of this study is to predict in vivo lung mass density for patients with interstitial lung disease using different gradient boosting decision tree (GBDT) algorithms based on measurements from lung ultrasound surface wave elastography (LUSWE) and pulmonary function testing (PFT). Methods: Age and weight of study subjects (57 patients with interstitial lung disease and 20 healthy subjects), surface wave speeds at three vibration frequencies (100, 150, and 200 Hz) from LUSWE, and predicted forced expiratory volume (FEV1% pre) and ratio of forced expiratory volume to forced vital capacity (FEV1%/FVC%) from PFT were used as inputs while lung mass densities based on the Hounsfield Unit from high resolution computed tomography (HRCT) were used as labels to train the regressor in three GBDT algorithms, XGBoost, CatBoost, and LightGBM. 80% (20%) of the dataset was used for training (testing). Results: The results showed that predictions using XGBoost regressor obtained an accuracy of 0.98 in the test dataset. Conclusion: The obtained results suggest that XGBoost regressor based on the measurements from LUSWE and PFT may be able to noninvasively assess lung mass density in vivo for patients with pulmonary disease.
Tricuspid valve regurgitation management with valve replacement Late Presentation of Traumatic Tricuspid Valve Regurgitation after Motor Vehicle Accident -- Role of 3D Echocardiography
Lee, Hong Seok , Naqvi, Tasneem Z.

Mayo Clinic

No container title available | February 23, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.161410780.09714167/v1 Get It

A 51-year-old unrestrained female driver with history of a high-speed motor vehicle accident had been followed due to progressively worsening tricuspid valve regurgitation (TR). Three dimensional (3D0 transesophageal echocardiogram (TEE) showed a TR jet through a perforation in the an avulsed anterior leaflet from the tricuspid valve and another central tricuspid TR jet regurgitation due to tricuspid leafletresulted from malcoaptation of the leaflets from tricuspid annulus annular dilatation.
The Great Debate With IBD Biosimilars
Limdi, Jimmy K. , Farraye, Francis A.

Mayo Clinic

Crohn's & Colitis 360 | February 23, 2021 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/crocol/otab015 | PMID 36776664 Get It

Abstract The relatively high cost of anti-TNF agents and looming or actual expiry of patents for several biologics have led to the development of “highly similar” versions of the “originator” drugs called “biosimilars.” The approval of biosimilars has been based on “extrapolation,” whereby approval is granted in licensed indications for the reference product without the need for clinical trials. We discuss efficacy and safety data in support of biosimilar use from prospective studies, switching from originator biologic, impact on immunogenicity, pharmaco-economic, and practical considerations for clinicians.
Reconstruction of the Medial Ulnar Collateral Ligament of the Elbow: The Docking Technique
Song, Bryant M. , Wilbur, Ryan R. , Camp, Christopher L.

Mayo Clinic

Video Journal of Sports Medicine | February 23, 2021 | Volume: 1 | Issue: 1 | Pages: No page available

10.1177/2635025421994110 | PMID 40309744 Get It

Background: The medial ulnar collateral ligament (MUCL) is the primary restraint to valgus force on the elbow. Since the first description of MUCL reconstruction by Jobe et al in 1986, many technical advancements have been implemented to improve outcomes and reduce complications. The docking technique has emerged as one of the most commonly used techniques. Indications: Following repetitive stress on the elbow during the overhead throwing motion, the MUCL may become attenuated, insufficient, or rupture completely. Although nonoperative treatment with rest and therapy is often the initial treatment of choice, individuals who fail conservative measures may require MUCL reconstruction. Technique Description: The major steps of the procedure are (1) harvesting of palmaris longus autograft, (2) incision and exposure, (3) preparation of ulnar tunnel, (4) preparation of docking site on medial epicondyle, (5) graft passage, (6) graft tensioning and length determination, (7) final fixation, and (8) closure. Results: This procedure allows for reconstruction of the MUCL, restoration of valgus stability to the elbow, and return to play rates of 80% to 95%. The docking technique has advantages over previously described MUCL reconstruction techniques in that it minimizes injury to the flexor pronator mass, avoids the ulnar nerve, allows for robust graft tensioning, and reduces the amount of bone removed from the medial epicondyle. Discussion/Conclusion: The docking technique, as described in this video demonstration, is the most common MUCL reconstruction technique used today. When precise surgical steps are followed, complication rates are low and patient outcomes are favorable.